Public Release: 

The Tasmanian tiger had a brain structure suited to a predatory life style

Brain scans suggest the action-planning part of the cortex was large in these extinct predators

PLOS

IMAGE

IMAGE: This photo is of a pair of Thylacines, a male and female. The Thylacine (Thylacinus cynocephalus) is a large, carnivorous marsupial also known as the Tasmanian Tiger or Tasmanian Wolf.... view more

Credit: Smithsonian Institutional Archives, 1904

Scans of preserved Tasmanian tiger brains suggest that these extinct predators devoted more of the cortex to complex cognition associated with predation compared to modern Tasmanian devils, according to a study published January 18, 2017 in the open-access journal PLOS ONE by Gregory Berns from Emory University, US, and Ken Ashwell from University of New South Wales, Australia.

The Tasmanian tiger, or thylacine, was a carnivorous marsupial and the apex predator in Tasmania. But the last one died in 1936 and little is known about the species' natural behavior. However, some behaviors can be inferred from brain structure, so Berns and Ashwell scanned two thylacine brains and reconstructed neural connections. The researchers also compared the structure of thylacine brains with that of Tasmanian devil brains.

The researchers found that thylacine brains had larger caudate zones than Tasmanian devil brains. This suggests that thylacines devoted more of their cortex to complex cognition, particularly action planning and possibly even decision making. This fits with the ecological niches of these two animals: Tasmanian devils are scavengers while thylacines were hunters, and the latter foraging strategy entails more planning.

###

In your coverage please use this URL to provide access to the freely available paper: http://dx.plos.org/10.1371/journal.pone.0168993

Citation: Berns GS, Ashwell KWS (2017) Reconstruction of the Cortical Maps of the Tasmanian Tiger and Comparison to the Tasmanian Devil. PLoS ONE 12(1): e0168993. doi:10.1371/journal.pone.0168993

Funding: The TTM-Trial was funded by independent research grants from the Swedish Heart Lung Foundation; Arbetsmarknadens Försäkringsaktiebolag Insurance Foundation; Swedish Research Council; regional research support, Region Skåne; governmental funding of clinical research within the Swedish National Health Services; Thelma Zoega Foundation; Krapperup Foundation; Thure Carlsson Foundation; Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research; Skåne University Hospital, Sweden; TrygFonden, Denmark; the European Clinical Research Infrastructures Network; and the European Critical Care Research Network. There was no commercial funding. Funding organizations neither had any access to the data nor had any influence on the analysis or interpretation.

Competing Interests: The authors have declared that no competing interests exist.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.